Overview

Data as of July 02, 2020 06:02 pm EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights

May 07, 2020

CONSHOHOCKEN, Pa. , May 07, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and highlights: “Madrigal continued to make progress toward our clinical development and business objectives during the first quarter of 2020,
Summary Toggle Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction

April 14, 2020

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic. PDFF vs NASH resolution (ROC) PRO-C3/C3M ratio
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

February 26, 2020

CONSHOHOCKEN, Pa. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf